Mineralys Therapeutics, Inc. Common Stock
Stock Chart, Company Information, and Scan Results
Stock Market Guides is not a financial advisor. Our content is strictly educational and should not be considered financial advice.
Mineralys Therapeutics, Inc. Common Stock Company Information, Fundamentals, and Technical Indicators
Mineralys Therapeutics, Inc., a biopharmaceutical company, develops medicines to target diseases driven by dysregulated aldosterone in the United States. It is developing lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of cardiorenal conditions affected by dysregulated aldosterone, such as hypertension, chronic kidney disease, and obstructive sleep apnea. The company was formerly known as Catalys SC1, Inc. and changed its name to Mineralys Therapeutics, Inc. in May 2020. Mineralys Therapeutics, Inc. was incorporated in 2019 and is headquartered in Radnor, Pennsylvania.
Mineralys Therapeutics, Inc. Common Stock In Our Stock Scanner
As of Sep 02, 2026
Join Our Free Email List
Get emails from us about ways to potentially make money in the stock market.